Request Demo
Last update 05 Dec 2025
CEA targeted CAR-T(Chongqing Precision Biotech)
Last update 05 Dec 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms C-13-X |
Target |
Action modulators |
Mechanism CEACAM5 modulators(Carcinoembryonic antigen related cell adhesion molecule 5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with CEA targeted CAR-T(Chongqing Precision Biotech)NCT07247396
A Clinical Trial to Evaluate the Safety and Efficacy of CEA-Directed CAR-T Cell Immunotherapy in Patients With Advanced Colorectal Cancer and Peritoneal Metastases Following Cytoreductive Surgery
NCT07250386
A Clinical Study to Evaluate the Safety and Efficacy of CEA-Targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients With CEA-Positive Advanced Malignant Solid Tumors
NCT07179692
Clinical Study of CEA-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CEA-Positive Malignant Solid Tumors
100 Clinical Results associated with CEA targeted CAR-T(Chongqing Precision Biotech)
Login to view more data
100 Translational Medicine associated with CEA targeted CAR-T(Chongqing Precision Biotech)
Login to view more data
100 Patents (Medical) associated with CEA targeted CAR-T(Chongqing Precision Biotech)
Login to view more data
100 Deals associated with CEA targeted CAR-T(Chongqing Precision Biotech)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Colorectal Adenocarcinoma | Phase 1 | China | 03 Nov 2025 | |
| Secondary malignant neoplasm of peritoneum | Phase 1 | China | 03 Nov 2025 | |
| Breast Cancer | Phase 1 | China | 13 Oct 2025 | |
| Colonic Cancer | Phase 1 | China | 12 Sep 2025 | |
| Esophageal Carcinoma | Phase 1 | China | 12 Sep 2025 | |
| Rectal Cancer | Phase 1 | China | 12 Sep 2025 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 12 Dec 2024 | |
| Recurrent lung cancer | Phase 1 | China | 12 Dec 2024 | |
| Small Cell Lung Cancer | Phase 1 | China | 12 Dec 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 24 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NEWS | ASCO2025 Manual  | Phase 1 | 15 | wqoaycztnr(bofhaopghx) = kyslryuzgf epadivfigo (tlxjlxiipg ) View more | Positive | 08 Sep 2025 | ||
NEWS Manual | Phase 1 | 15 | fvrmusqlju(fuyuwoiyla) = pwwmeqyzpi iddktrcxkh (rzozqkeuyz ) View more | Positive | 14 Aug 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free